Last reviewed · How we verify
Fusidic Acid 1% M/R Eye Drops
Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G, preventing bacterial growth in ocular infections.
Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G, preventing bacterial growth in ocular infections. Used for Bacterial eye infections (conjunctivitis, blepharitis), Ocular infections caused by gram-positive bacteria.
At a glance
| Generic name | Fusidic Acid 1% M/R Eye Drops |
|---|---|
| Sponsor | Barzilai Medical Center |
| Drug class | Bacterial protein synthesis inhibitor / Antibiotic |
| Target | Elongation factor G (EF-G) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Fusidic acid is a bacteriostatic antibiotic that targets gram-positive bacteria by inhibiting elongation factor G (EF-G), a key component of the bacterial protein synthesis machinery. This prevents the translocation of peptides during translation, effectively halting bacterial protein production. The 1% modified-release formulation provides sustained drug delivery to ocular tissues for prolonged antimicrobial activity.
Approved indications
- Bacterial eye infections (conjunctivitis, blepharitis)
- Ocular infections caused by gram-positive bacteria
Common side effects
- Eye irritation
- Transient blurred vision
- Conjunctival hyperemia
Key clinical trials
- The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fusidic Acid 1% M/R Eye Drops CI brief — competitive landscape report
- Fusidic Acid 1% M/R Eye Drops updates RSS · CI watch RSS
- Barzilai Medical Center portfolio CI